This Combination Therapy Could Help Change Cancer Treatment - Take A Deeper Look Into Allarity Therapeutics' Trial

CAMBRIDGE, MA / ACCESSWIRE / April 17, 2023 / Allarity Therapeutics (NASDAQ:ALLR) dosed its first patient in Phase 1b of its clinical trial for the novel combination therapy of two drugs, stenoparib and dovitinib. The company is evaluating the safety, dosing, and potential therapeutic benefit of this combination therapy on advanced solid tumors, including ovarian cancer.

Foto: Accesswire

One in 78 women will reportedly develop ovarian cancer during their lifetime, though the disease normally affects older women. It is expected that over 19,000 women will be diagnosed with ovarian cancer in 2023, and this form of cancer is the fifth most common cause of cancer deaths for women. The ovarian cancer treatment market was worth $3.2 billion in 2022 and is expected to reach $6.36 billion by 2027, growing at a compound annual growth rate (CAGR) of 14.4% during the forecast period. However, there continues to be a need for new and more effective treatments for ovarian cancer.

Both stenoparib and dovitinib have shown promising results for cancer treatment in the past. Stenoparib is a poly-ADP ribose polymerase (PARP) inhibitor, which blocks the repair of single-stranded DNA within cancerous cells. Dovitinib is a pan-tyrosine kinase inhibitor (TKI) with an anti-angiogenic activity that cuts off the blood supply to the cancerous region, resulting in an increase in tumor DNA damage, the repair of which can then be blocked by Stenoparib. Now, Allarity Therapeutics is exploring the potential for a combination therapy that uses these two drugs to tackle solid tumors.

A Combination That Could Help Change Cancer Treatment

Dr. Mansoor Raza Mirza, a leading expert in oncology and Chief Oncologist in the Department of Oncology at Copenhagen University Hospital, is a member of the Scientific Advisory Board of Allarity. In a recent interview, he shared his excitement in following the results of this trial. Though combination therapy is not unusual, according to Dr. Mirza, this unique combination could be particularly efficacious and serve a major unmet need in cancer patients. The science and rationale supporting this combination therapy are strong, and Dr. Mirza is looking forward to the clinical evidence forthcoming from the trial.